Uterine Serous Carcinoma (USC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Uterine Serous Carcinoma (USC) Market Outlook

Thelansis’s “Uterine Serous Carcinoma (USC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uterine Serous Carcinoma (USC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Uterine Serous Carcinoma (USC) Overview

Uterine serous carcinoma (USC) commonly arises on the surface of endometrial polyps in the background of an atrophic endometrium. The most representative non-endometrioid endometrial carcinoma is uterine serous carcinoma (USC), which accounts for about 10% of all endometrial cancers. Endometrioid carcinoma of the endometrium is the most common histological subtype of endometrial cancer, accounting for 85 - 90% of cases and is generally associated with a lower risk for progression and favorable prognosis particularly for low-grade disease. USC is microscopically characterized by (1) papillae with or without a fibrovascular core, (2) marked nuclear atypia, (3) slit-like spaces, (4) solid growth, and (5) scant cytoplasm. Despite being the second most common type of endometrial cancer, USC is still considered a relatively rare tumor. Patients with USC are often diagnosed at an earlier disease stage compared to endometrioid subtype endometrial cancer but remain at a higher risk for relapse and have an overall worse prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer.

• • Endometrial cancer is one of the most common gynecological malignancies in developed countries, accounting for about 65,000 newly diagnosed cases estimated in the United States in 2020. 
  • A rising incidence of endometrial cancer by more than 20,000 new cases per year has been observed in the last decade, likely attributable to the aging of populations and increased prevalence of obesity as a key indicator in the developed nations.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: